stockrow
Sunday 8 November 2026
Export MIRA’s income statement to Excel — free account
MIRA Pharmaceuticals, Inc.
MIRAHealthcare Drug Manufacturers General
- EPS
- +66.7%
- Free cash flow
- −50.8%
Quarter to June 2026, against a year earlier
0.57
0.03
+5.56%
Follow MIRA
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Gross margin, % | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
| EBT | — | — | — | — | 0 | (2) | (7) | (12) | (8) | (10) | (9) | +173.7% | ||||||
| EBT margin, % | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| Net income | — | — | — | — | 0 | (2) | (7) | (12) | (8) | (10) | (9) | +173.7% | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | |||||
| Earnings | — | — | — | — | 0.00 | (0.15) | (0.40) | (0.86) | (0.51) | (1.35) | (1.42) | n/m | ||||||
| Cash flow | — | — | — | — | 0.00 | (0.09) | (0.32) | (0.33) | (0.36) | (0.20) | (0.11) | +111.9% | ||||||
| Capex | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | ||||||
| Free cash flow | — | — | — | — | 0.00 | (0.09) | (0.32) | (0.33) | (0.36) | (0.20) | (0.11) | +111.9% | ||||||
| Book value | — | — | — | — | 0.00 | 0.15 | (0.03) | 0.31 | 0.14 | 0.44 | 0.19 | n/m | ||||||
| Shares, m | — | — | — | — | 15 | 15 | 18 | 14 | 15 | 24 | 32 | +10.0% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | 0 | — | |||||
| P/S | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| P/B | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | 0 | (1) | (6) | (5) | (6) | (5) | (5) | +132.9% | |||||
| Capex | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Free cash flow | — | — | — | — | 0 | (1) | (6) | (5) | (6) | (5) | (5) | +132.9% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | — | — | 0 | 2 | (1) | 4 | 2 | 10 | 8 | n/m | |||||
| Net debt | — | — | — | — | 0 | (3) | 0 | (5) | (3) | (11) | (8) | n/m | ||||||
| Shareholders’ equity | — | — | — | — | 0 | 2 | (1) | 4 | 2 | 10 | 8 | n/m | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | — | — | 0.00 | (128.65) | (335.04) | (413.86) | (199.93) | (456.59) | (684.27) | (456.6) pt | |||||
| ROIC | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (12,016.10) | 0.0 pt | ||||||
| ROE | — | — | — | — | 0.00 | (197.93) | (847.73) | (634.30) | (238.90) | (508.28) | (710.85) | (508.3) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | — | — | 6 | 3 | 5 | 2 | — | (30.7%) | |||||
| Revenue/emp, $m | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | — | n/m | ||||||
Negative figures in brackets.
estimates
MIRA Pharmaceuticals, Inc. vs peers in Drug Manufacturers General (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| GSK GSK PLC Sponsored ADR | $101.0B | 16.7× | 15.3× | +3.75% (above 0%: growing) | −14.73% (below 0%: shrinking) | +62.44% (above 0%: growing) | 73.11% | 23.93% | Compare |
| BIIB Biogen Inc. | $36.1B | 105× | 46.4× | +10.63% (above 0%: growing) | n/m | −69.25% (below 0%: shrinking) | 73.31% | 4.58% | Compare |
| OGN Organon & Co. | $3.6B | 17.3× | 6.2× | −1.75% (below 0%: shrinking) | +1.64% (above 0%: growing) | +118.79% (above 0%: growing) | 55.21% | 23.19% | Compare |
| GRFS Grifols, S.A. | $2.2B | 18.2× | — | +9.37% (above 0%: growing) | +59.78% (above 0%: growing) | +4.11% (above 0%: growing) | 39.56% | 19.22% | Compare |
| AMRN Amarin Corporation PLC | $244.0M | — (loss-making) | — (loss-making) | −20.37% (below 0%: shrinking) | n/m | +172.64% (above 0%: growing) | 40.91% | (5.97%) | Compare |
| NSRX Nasus Pharma Ltd. | $34.1M | — | — | — | — | −486.98% (below 0%: shrinking) | — | — | Compare |
| MIRA MIRA Pharmaceuticals, Inc. | $22.7M | — (loss-making) | — | — | n/m | −50.76% (below 0%: shrinking) | — | 0.00% | |
| SCLX Scilex Holding Company | $12.0M | — (loss-making) | — (loss-making) | −22.78% (below 0%: shrinking) | n/m | −203.76% (below 0%: shrinking) | 51.88% | (385.02%) | Compare |
| MDCX Medicus Pharma Ltd | $3.5M | — (loss-making) | — | — | n/m | −27.70% (below 0%: shrinking) | — | 0.00% | Compare |
| Median of peers | $1.2B | 17.8× | 15.3× | +1.00% | +1.64% | −11.80% | 53.55% | 4.58% |
Pay and ownership Proxy statement filed 28 July 2026
Ownership
Directors and executive officers, together
19.89%
Erez Aminov
19.34%
Brian McNulty
11.50%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement